AYTU Relative Valuation
AYTU's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AYTU is overvalued; if below, it's undervalued.
Historical Valuation
Aytu Biopharma Inc (AYTU) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.90. The fair price of Aytu Biopharma Inc (AYTU) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：2.15
Fair
-2.42
PE
1Y
3Y
5Y
Trailing
Forward
-2.19
EV/EBITDA
Aytu Biopharma Inc. (AYTU) has a current EV/EBITDA of -2.19. The 5-year average EV/EBITDA is -1.46. The thresholds are as follows: Strongly Undervalued below -21.26, Undervalued between -21.26 and -11.36, Fairly Valued between 8.44 and -11.36, Overvalued between 8.44 and 18.34, and Strongly Overvalued above 18.34. The current Forward EV/EBITDA of -2.19 falls within the Historic Trend Line -Fairly Valued range.
-1.39
EV/EBIT
Aytu Biopharma Inc. (AYTU) has a current EV/EBIT of -1.39. The 5-year average EV/EBIT is 12.06. The thresholds are as follows: Strongly Undervalued below -98.77, Undervalued between -98.77 and -43.36, Fairly Valued between 67.47 and -43.36, Overvalued between 67.47 and 122.88, and Strongly Overvalued above 122.88. The current Forward EV/EBIT of -1.39 falls within the Historic Trend Line -Fairly Valued range.
0.38
PS
Aytu Biopharma Inc. (AYTU) has a current PS of 0.38. The 5-year average PS is 0.41. The thresholds are as follows: Strongly Undervalued below -0.55, Undervalued between -0.55 and -0.07, Fairly Valued between 0.89 and -0.07, Overvalued between 0.89 and 1.37, and Strongly Overvalued above 1.37. The current Forward PS of 0.38 falls within the Historic Trend Line -Fairly Valued range.
-1.77
P/OCF
Aytu Biopharma Inc. (AYTU) has a current P/OCF of -1.77. The 5-year average P/OCF is -1.03. The thresholds are as follows: Strongly Undervalued below -4.66, Undervalued between -4.66 and -2.84, Fairly Valued between 0.79 and -2.84, Overvalued between 0.79 and 2.61, and Strongly Overvalued above 2.61. The current Forward P/OCF of -1.77 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Aytu Biopharma Inc. (AYTU) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.21. The thresholds are as follows: Strongly Undervalued below -4.84, Undervalued between -4.84 and -2.53, Fairly Valued between 2.10 and -2.53, Overvalued between 2.10 and 4.41, and Strongly Overvalued above 4.41. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Aytu Biopharma Inc (AYTU) has a current Price-to-Book (P/B) ratio of 0.91. Compared to its 3-year average P/B ratio of 0.43 , the current P/B ratio is approximately 112.81% higher. Relative to its 5-year average P/B ratio of 0.51, the current P/B ratio is about 80.14% higher. Aytu Biopharma Inc (AYTU) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -55.33%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -69.69% , the current FCF yield is about -100.00% lower.
0.96
P/B
Median3y
0.43
Median5y
0.51
-6.71
FCF Yield
Median3y
-55.33
Median5y
-69.69
Competitors Valuation Multiple
The average P/S ratio for AYTU's competitors is 0.00, providing a benchmark for relative valuation. Aytu Biopharma Inc Corp (AYTU) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -16.21%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of AYTU increased by 31.76% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 6.59 to 14.15.
The secondary factor is the Revenue Growth, contributed -16.21%to the performance.
Overall, the performance of AYTU in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Aytu Biopharma Inc (AYTU) currently overvalued or undervalued?
What is Aytu Biopharma Inc (AYTU) fair value?
How does AYTU's valuation metrics compare to the industry average?
What is the current P/B ratio for Aytu Biopharma Inc (AYTU) as of Dec 05 2025?
What is the current FCF Yield for Aytu Biopharma Inc (AYTU) as of Dec 05 2025?
What is the current Forward P/E ratio for Aytu Biopharma Inc (AYTU) as of Dec 05 2025?